ストックスクリーナーアプリを入手
1.61
0.62%
-0.01
アフターアワーズ：
1.62
0.01
+0.62%
前日終値:
$1.62
開ける：
$1.66
24時間の取引高:
775.22K
Relative Volume:
0.73
時価総額：
$110.07M
収益：
$593.00K
当期純損益:
$-45.85M
株価収益率:
-2.3452
EPS:
-0.6865
ネットキャッシュフロー:
$-37.97M
1週間 パフォーマンス:
-6.94%
1か月 パフォーマンス:
-17.01%
6か月 パフォーマンス:
-22.60%
1年 パフォーマンス:
-47.39%
1日の値動き範囲:
$1.61
$1.715
1週間の範囲:
$1.55
$1.755
52週間の値動き範囲:
$1.48
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
名前
Cardiff Oncology Inc
セクター
電話
858-952-7570
住所
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.61 | 110.75M | 593.00K | -45.85M | -37.97M | -0.6865 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | 開始されました | Noble Capital Markets | Outperform |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2025-06-24 | 開始されました | Jefferies | Hold |
| 2024-09-06 | 開始されました | Craig Hallum | Buy |
| 2022-01-05 | 開始されました | William Blair | Outperform |
| 2021-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-09 | 再開されました | Maxim Group | Buy |
| 2020-10-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Cardiff Oncology Inc (CRDF) 最新ニュース
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Can Cardiff Oncology Inc reach all time highs this yearTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn
Noble Financial Issues Optimistic Estimate for CRDF Earnings - MarketBeat
Growth Review: What is the PEG ratio of Cardiff Oncology Inc2026 Buyback Activity & Risk Controlled Daily Plans - baoquankhu1.vn
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF) - The Globe and Mail
Vanguard (NASDAQ: CRDF) reports 0 shares after Jan 12, 2026 realignment - Stock Titan
Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target By Investing.com - Investing.com Canada
Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target - Investing.com
William Blair reiterates Cardiff Oncology stock rating on drug data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy - Investing.com
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy By Investing.com - Investing.com Canada
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
CRDF: Onvansertib plus FOLFIRI+BEV achieved a 72% response rate and strong PFS in RAS mutated CRC - TradingView
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar - MarketBeat
Cardiff Oncology Inc to Host KOL Webinar Transcript - GuruFocus
Published on: 2026-03-26 02:49:36 - baoquankhu1.vn
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - 富途牛牛
Two cancer specialists join Cardiff talk on first-line colon cancer - Stock Titan
Cardiff Oncology to present preclinical data at cancer conference By Investing.com - Investing.com Canada
Cardiff Oncology to present preclinical data at cancer conference - Investing.com
Cardiff Oncology Presents Promising Preclinical Data on Onvansertib at AACR Annual Meeting 2026 - Quiver Quantitative
Cardiff Oncology to Present Preclinical Data with Highly - GlobeNewswire
Levels Update: Can Cardiff Oncology Inc reach all time highs this year - baoquankhu1.vn
Ladenburg Thalmann Initiates Coverage of Cardiff Oncology (CRDF) with Buy Recommendation - MSN
IPO Launch: Whats the analyst consensus on Cardiff Oncology IncWeekly Trade Review & High Conviction Trade Alerts - baoquankhu1.vn
Jobs Data: Is Cardiff Oncology Inc undervalued by DCF analysisWeekly Investment Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
Rate Cut: Can Cardiff Oncology Inc reach all time highs this yearPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Cardiff Oncology (STU:XE7C) NonCurrent Deferred Revenue : €0.00 Mil (As of Dec. 2025) - GuruFocus
What is Zacks Research’s Forecast for CRDF FY2027 Earnings? - Defense World
What is Zacks Research's Forecast for CRDF FY2027 Earnings? - MarketBeat
CRDF Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen - MarketBeat
Cardiff Oncology, Inc. (CRDF) - Minichart
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
CRDF: 10-K Filing Prompts Model Update - Yahoo Finance
HC Wainwright Issues Optimistic Outlook for CRDF Earnings - MarketBeat
Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC - Defense World
CRDF: Onvansertib shows 72% ORR and robust PFS in RAS-mutated mCRC, advancing to phase III trials - TradingView
Piper Sandler Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price - MarketBeat
CRDF: Today's Analyst Ratings and Price Target Adjustment | CRDF Stock News - GuruFocus
Cardiff Oncology advances onvansertib program in colorectal cancer - TipRanks
3 ‘Strong Buy’ Stocks to Buy Today, 2/25/2026, According to Top Analysts - TipRanks
Onvansertib Phase 2 results boost Cardiff Oncology (NASDAQ: CRDF) plans - Stock Titan
Cardiff Oncology Reports Full Year 2025 Results And Provides Business Update - Nasdaq
Cardiff Oncology Q4 2025 Results: Loss of $7.2M Beats Analyst Forecasts | Financial ReportNews and Statistics - IndexBox
Cardiff Oncology earnings beat by $0.08, revenue topped estimates - Investing.com Canada
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results - MarketBeat
Cardiff Oncology: Fourth Quarter Financial Results Overview - Bitget
Cardiff Oncology Inc (CRDF) 財務データ
収益
当期純利益
現金流量
EPS
Cardiff Oncology Inc (CRDF) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
1.52%
0.51%
大文字化:
|
ボリューム (24 時間):